In native PAGE, we noticed LC aggregates (> 720 kDa) and high molecular weight (HMW) aggregates incapable of migrating into the gel after 1 day of incubation (Fig. as dimers, 50% of which were linked by disulfide bridges. Our results suggest that cleavage into LC monomers is required intended for efficient amyloid formation. The kinetics of AL LC displayed a transition point in concentration dependence, which MM LC lacked. Duocarmycin A The lack of concentration dependence of MM LC aggregation kinetics suggests that conformational change from the light chain is rate-limiting for these proteins. Aggregation kinetics displayed two distinct phases, which corresponded to the formation of oligomers and amyloid fibrils, respectively. EGCG specifically inhibited the second aggregation phase and induced the formation of SDS-stable, non-amyloid LC aggregates. Our data suggest that EGCG intervention does not depend on the person LC sequence and is similar to the mechanism noticed for amyloid- and -synuclein. Keywords: amyloid, immunoglobulin fold, multiple myeloma, protein assimilation, protein purification, AL amyloidosis, EGCG == Introduction == Systemic light chain amyloidosis (AL)2is the most common form of systemic amyloidosis (1), but it is still a rare disease with an incidence of 67 in 1, 000, 000 people (2). Underlying AL pathology is a clonal plasma cell disorder, which produces an immunoglobulin light chain in the bone marrow with a unique sequence. These light chains are released into the blood (monoclonal gammopathy). When raised LC levels in serum overwhelm renal absorption, LC is also found in the urine. Full-length LC can be isolated from the urine of these patients (35). Clonal plasma cell disorders can present different types of pathologies; light chains form Duocarmycin A amyloid deposits in AL patients. Here, LC fibrils take up a conformation characterized by highly stable, intramolecular cross–sheets that stain with Congo red (6) and thioflavin T (ThT) (79). In contrast, amyloid deposits are not observed in patients suffering from multiple myeloma (MM), a malignant disease characterized by bone marrow failure and bone destruction. The two contrasting pathologies of LC gammopathies raise the question of which Duocarmycin A factors determine amyloid formation. Amyloid formation could be initiated (a) by the sequences of the individual light chains, (b) by large levels of light chain expression, (c) by posttranslational modification of the LC, (d) by fragmentation from the light chain, or (e) by a combination of these factors. A possible modification would be the formation or cleavage of intermolecular intradomain disulfide bonds. The variable (VL) and constant (CL) domains of LC proteins are connected by a short becoming a member of domain (1013). Both contain an intradomain disulfide bridge (1015) between Cys-23 and Cys-104. Additionally , the constant domain name can form interchain disulfide bonds to Ig heavy or light chains (1013) via its conserved Cys-127 residue (16, 17). Previous quantitative studies possess focused on a small number of recombinant proteins spanning the variable domain name of the LC proteins (1826). These systems cannot treat the relevance of interdomain interactions in LC amyloid formation. The significance of full-length LC intended for amyloid formation is not yet fully comprehended (2730). Our study, for the first time, quantifies stabilities and amyloid formation propensities Rabbit polyclonal to PIWIL1 of nine authentic, full-length LC proteins that we isolated from the urine of patients (4 with AL, 5 with MM). Our study tested whether AL and MM light chains had inherently diverse stabilities or amyloid formation propensities. We found that both AL and MM full-length Duocarmycin A light chains formed amyloid aggregatesin vitro, but only under conditions that cleaved intermolecular disulfide bonds. Aggregation kinetics were unique for each LC protein and correlated only weakly with thermodynamic stability. Treatment intended for the plasma cell clone pathology is present in the form of chemotherapy, but the direct treatment of amyloid pathology is still under analysis. Recently, we could show that the green tea polyphenol epigallocatechin-3-gallate (EGCG) redirects Duocarmycin A amyloid formation of amyloid- and -synuclein into inert shadowy aggregates (3133). A case report of a patient who self-administered EGCG after several cycles of chemotherapy found that EGCG reduced LC deposits in the patient’s heart and extended the patient’s life over a period of several years (34). A reduction in cardiac pathology was observed in some but not all patients treated with EGCG (35). This.